Giorgino F, Pedrini M T, Matera L, Smith R J
Research Division, Joslin Diabetes Center, and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
J Biol Chem. 1997 Mar 14;272(11):7455-63. doi: 10.1074/jbc.272.11.7455.
The stimulation of phosphatidylinositol (PI) 3-kinase by insulin-like growth factor I (IGF-I) in L6 cultured skeletal muscle cells is inhibited by the glucocorticoid dexamethasone. The objective of this study was to investigate the mechanism of dexamethasone action by determining its effects on the expression of the p85alpha and p85beta regulatory subunit isoforms of PI 3-kinase, their coupling with the p110 catalytic subunit, and their association with insulin receptor substrate 1 (IRS-1) in response to IGF-I stimulation. Dexamethasone induced a 300% increase in p85alpha protein content in the L6 cultured myoblast cell line, whereas it increased p110 content by only 38% and had no effect on p85beta. The increase in p85alpha protein was associated with a coordinate increase in p85alpha mRNA. Stimulation with IGF-I induced the association of p85alpha and p85beta with IRS-1, and this was accompanied by increased amounts of the p110 catalytic subunit and markedly increased PI 3-kinase activity in IRS-1 immunoprecipitates. In cells treated with dexamethasone, greater amounts of p85alpha and lower amounts of p85beta, respectively, were found in IRS-1 immunoprecipitates, such that the alpha/beta ratio was markedly higher than in control cells. In spite of the increase in both total and IRS-1-associated p85alpha following dexamethasone treatment, IRS-1-associated p110 catalytic subunit and PI 3-kinase activity were decreased by approximately 50%. Thus, dexamethasone induces a specific increase in expression of the p85alpha regulatory subunit that is not associated with a coordinate increase in the p110 catalytic subunit of PI 3-kinase. As a consequence, in dexamethasone-treated cells, p85alpha that is not coupled with p110 competes with both p85alpha.p110 and p85beta.p110 complexes for association with IRS-1, leading to increased p85alpha but decreased p85beta, p110, and PI 3-kinase activity in IRS-1 immunoprecipitates.
胰岛素样生长因子I(IGF-I)对L6培养骨骼肌细胞中磷脂酰肌醇(PI)3激酶的刺激作用受到糖皮质激素地塞米松的抑制。本研究的目的是通过确定地塞米松对PI 3激酶的p85α和p85β调节亚基异构体表达的影响、它们与p110催化亚基的偶联以及它们在IGF-I刺激下与胰岛素受体底物1(IRS-1)的结合,来研究地塞米松的作用机制。地塞米松使L6培养的成肌细胞系中p85α蛋白含量增加了300%,而p110含量仅增加了38%,对p85β没有影响。p85α蛋白的增加与p85α mRNA的相应增加有关。用IGF-I刺激可诱导p85α和p85β与IRS-1结合,同时IRS-1免疫沉淀物中p110催化亚基的量增加,PI 3激酶活性显著增强。在用糖皮质激素处理的细胞中,IRS-1免疫沉淀物中分别发现了更多的p85α和更少的p85β,因此α/β比值明显高于对照细胞。尽管地塞米松处理后总p85α和与IRS-1相关的p85α均增加,但与IRS-1相关的p110催化亚基和PI 3激酶活性却降低了约50%。因此,地塞米松诱导p85α调节亚基的表达特异性增加,而这与PI 3激酶的p110催化亚基的相应增加无关。结果,在用地塞米松处理的细胞中,未与p110偶联的p85α与p85α.p110和p85β.p110复合物竞争与IRS-1的结合,导致IRS-1免疫沉淀物中p85α增加,但p85β、p110和PI 3激酶活性降低。